Skye Bioscience Inc.

10/15/2025

Dr. Louis Aronne, MD, past President, The Obesity Society; past Chairman, American Board of Obesity Medicine; and clinical advisor to Skye, shared his insights on our CBeyond™ Phase 2a Data.

For a more in-depth look at the data, from study design and dosing to topline outcomes and next steps, please see our most recent presentation: https://ir.skyebioscience.com/company-information/ir-calendar-webcasts/detail/20251006-cbeyond-phase-2a-clinical-trial-topline-data-conference-call-webcast

10/14/2025

We’re taking a quick look at some of the Phase 2a safety profile highlights, including both neuropsychiatric and gastrointestinal tolerability.

For a deeper look at safety results from our Phase 2a trial, please see last week’s conference call and webcast: https://ir.skyebioscience.com/company-information/ir-calendar-webcasts/detail/20251006-cbeyond-phase-2a-clinical-trial-topline-data-conference-call-webcast

10/10/2025

Dr. Sean Wharton, MD, Director of the Wharton Medical Clinic and clinical advisor at Skye, recently shared his views on our CBeyond™ Phase 2a study.

To hear more from Dr. Wharton and the Skye leadership team, the full webcast and transcript from this week's call are available here: https://ir.skyebioscience.com/company-information/ir-calendar-webcasts/detail/20251006-cbeyond-phase-2a-clinical-trial-topline-data-conference-call-webcast

10/06/2025

Featuring insights from CEO Punit Dhillon, CMO Puneet Arora, MD, MS, FACE, COO Tu Diep, MSc, CSO Chris Twitty, PhD, Dr. Louis Aronne, MD, FACEP, and Dr. Sean Wharton, MD, FRCPC, PharmD, the recording of today’s webcast is now available online.

For the full recording, please see our website: https://ir.skyebioscience.com/company-information/ir-calendar-webcasts

10/06/2025

Today, we reported topline Phase 2a data from our 26-week Phase 2a CBeyond™.

Including details on our monotherapy arm and in combination with semaglutide - as well as further information surrounding weight-loss characteristics, tolerability, and more - visit our website to view today's release: https://ir.skyebioscience.com/news-releases/detail/244/skye-bioscience-reports-topline-cbeyond-phase-2a-data-from-nimacimab-monotherapy-and-combination-clinical-trial

09/22/2025

Effectively treating a multifaceted disease like obesity requires different approaches and mechanisms for weight loss.

Skye COO Tu Diep shares some of the feedback we've been receiving from obesity specialists, along with how nimacimab's distinct mechanism of action fits into the current treatment landscape.

View the full version of the video on our Spotlight page: https://ir.skyebioscience.com/spotlight

09/19/2025

Today's presentation at the European Association for the Study of Diabetes Annual Meeting shared results from our Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease.

Demonstrating that nimacimab was safe, well-tolerated, and exhibited predictable pharmacokinetics and low immunogenicity, review the full presentation through our website: https://ir.skyebioscience.com/spotlight

09/18/2025

A recent major study in the journal PNAS compared daily calorie burn for people in 34 different countries and cultures around the world, finding total calorie burn per day similar across populations.

These findings have led scholars to conclude that the strong evidence indicates diet is the major driver in weight gain.

While physical activity does play a role in weight loss and maintaining a healthy lifestyle, the complicated biology surrounding obesity and the messaging around inactivity need to change to find better solutions to treating obesity.

Read an insightful exploration of the findings on NPR here:

One explanation for the rise in obesity in industrialized countries is that people burn fewer calories than people in countries where obesity is rare. A major study finds that's not the case.

09/17/2025

The Obesity Science & Innovation Summit was an excellent opportunity to explore the future of obesity treatment and weight loss, with Skye CEO Punit Dhillon joining a group of industry leaders for the keynote panel.

Highlighting the market opportunity and differentiation of nimacimab, this session shared groundbreaking modalities and new targets, alongside the need to reduce side effects and improve patient outcomes.

To learn more about our pipeline, visit our website here: https://skyebioscience.com/

09/15/2025

What drives you?

Skye COO Tu Diep, MSc, is driven by good science designed to help people live healthier lives.

We recently spoke to Tu about his inspiration and journey in science and discovery. View the full version of the video here: https://www.youtube.com/watch?v=wezYibcplLk

09/12/2025

Why is nimacimab different?

Here’s a look at what differentiates our CB1 receptor inhibitor, with potential to avoid the baggage of past drugs and deliver weight loss without psychiatric side effects.

With Phase 2a data expected in Q3/Q4 of this year, learn more about Skye and our pipeline here: https://skyebioscience.com/

09/11/2025

The full recording of our virtual KOL event is now available, providing perspectives and insights on our upcoming Phase 2a CBeyond™ study and CB1 inhibition as a mechanism for weight loss.

View the full video here:

Skye’s CB1 inhibitor, nimacimab, demonstrates superior weight loss and differentiated mechanisms from monlunabant, and continues to show enhanced combination...